Objective historical variables enable higher reliability than the HEART Score.
Proven to lower the frequency of observation admissions.
The HEART Pathway® enables clear, objective protocols system-wide.
The HEART Pathway® is a revolutionary clinical algorithm that uses objective clinical data to risk stratify patients with chest pain, identifying patients who are unlikely to benefit from advanced cardiac diagnostic testing and who can be safely discharged home.
By using a statistical model based on the latest clinical validation studies, the HEART Pathway® puts unparalleled accuracy and precision in the hands of emergency medicine clinicians.
Chest pain is a top cause of US ED visits. Eight to ten million patients with chest pain present to an ED annually in the United States. Emergency providers care for patients with chest pain on virtually every shift. More than half of Emergency Department patients with chest pain receive lengthy cardiac evaluations in a chest pain unit or inpatient ward, with an annual cost $10-13 billion.
Less than ten percent of patients have an acute coronary syndrome (ACS). Two to five percent of patients with myocardial infarctions are inappropriately discharged from the ED every year. Missed ACS is a top cause of malpractice claims.
Robust support for administrative insights through our proprietary backend.
Emergency medicine, internal medicine, and cardiology benefit from our consistent scoring method.
Documented use of risk stratification supports chest pain center accreditation.
The HEART Pathway® is designed for more accurate risk stratification, identifying patients unlikely to benefit from hospitalization or stress testing/cardiac imaging who can safely be discharged home from the ED. This allows hospitals to focus on advanced care and diagnostic tests on the patients most likely to benefit. Studies have demonstrated the benefits of the HEART Pathway® compared to usual care. The HEART Pathway® randomized control trial (Mahler et al, Circ CVQO J, 2015.)
The HEART Pathway® assists with answering two important questions: "What is the likelihood that my patient’s presenting symptoms represent ACS?" and "what is the likelihood that my patient will have an ACS event in the near future (within 30 days)?"
The HEART Pathway® is freely available for personal use on mobile devices using iOS and iPadOS. You can download the app right now and start using the same groundbreaking risk stratification tool used in the HEART Pathway randomized-control trial (Mahler et al., 2015).
